$225.70-23.09% · 3M
Moving avg
1W+2.97%
1M-19.14%
3M-21.35%
6M-28.21%
YTD-43.60%
1Y-49.02%
3Y+24.46%
5Y+14.70%
52-week range
$262.210% of range$495.55
Company health
Value0/6
Growth3/6
Profitability4/6
Health3/6
Dividend0/6
Bull vs bear
Strengths
- Analysts see 94% upside to a $439 target
- Analyst consensus is "Buy"
- High return on equity (9829%)
- Revenue compounding 48% a year
- Net cash on the balance sheet
Risks
- Richly valued at 62.3x earnings
Key statistics
Valuation
Market cap
$30.20B
Enterprise value
$35.85B
P/E ratio (TTM)
62.33x
P/S ratio (TTM)
8.46x
EV/EBITDA
38.78x
Per share & returns
EPS (TTM)
$4.34
Dividend yield
0.00%
Beta (1Y)
0.27
30-day change
-19.14%
Trading
Volume (24h)
466.26K
Previous close
$223.95
Shares outstanding
133.81M
About Alnylam Pharmaceuticals, Inc.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Symbol
ALNY
Alnylam Pharmaceuticals, Inc. is a large-cap healthcare company in the Biotechnology industry. Its shares are listed on NASDAQ (United States) and trade under the ticker ALNY.
Frequently asked questions
What is Alnylam Pharmaceuticals, Inc.'s market cap?
Alnylam Pharmaceuticals, Inc. (ALNY) has a market capitalization of $30.20B.
What is Alnylam Pharmaceuticals, Inc.'s P/E ratio?
Alnylam Pharmaceuticals, Inc. trades at a price-to-earnings (P/E) ratio of 62.33.
What exchange does ALNY trade on?
ALNY trades on NASDAQ.
Appears in
Eli Lilly and CompanyLLY
$1,216.03-0.35%
$1.15T cap
Johnson & JohnsonJNJ
$261.33+0.18%
$629.78B cap
AbbVie Inc.ABBV
$250.78+0.81%
$443.08B cap
UnitedHealth Group IncorporatedUNH
$402.12-0.86%
$365.18B cap
Roche Holding AGSWX: ROP
CHF 362.30-0.88%
$354.73B cap
Merck & Co., Inc.MRK
$134.53+1.21%
$332.26B cap
Novartis AGSWX: NOVN
CHF 123.74-0.37%
$289.30B cap
AstraZeneca PLCLON: AZN
£117.08+0.05%
$245.01B cap